Sonidegib, also known by its trade name Odomzo, is an oral medication that inhibits the Hedgehog (Hh) signaling pathway. This pathway plays a crucial role in cell differentiation and tissue patterning during embryonic development, but it is also implicated in the growth and survival of certain cancer cells. Sonidegib specifically targets and inhibits the Smoothened (SMO) receptor, a key component of the Hh pathway.
